The 5xFAD transgenic mouse model is one of the most widely used and aggressively amyloidogenic Alzheimer's disease (AD) models available for research. This model co-expresses five familial AD mutations in amyloid precursor protein (APP) and presenilin 1 (PSEN1), leading to rapid and robust amyloid-beta (Aβ) plaque deposition beginning at a very young age[1]. The 5xFAD model has become a cornerstone for amyloid-focused AD research, providing valuable insights into disease mechanisms and therapeutic development[2].
This comprehensive page details the genetic construction, pathological features, behavioral phenotypes, research applications, and limitations of the 5xFAD model. It also covers recent advances and future directions in 5xFAD-based research.
The 5xFAD model was generated through co-injection of two transgenes encoding APP and PSEN1 with familial AD mutations under the control of separate neuronal-specific promoters[1:1]. This double-transgenic approach allows for co-expression of multiple disease-causing mutations in the same animal, creating a robust amyloid pathology model.
The APP transgene carries three FAD mutations, collectively known as the "Swedish," "Florida," and "London" mutations:
| Mutation | Location | Effect | Reference |
|---|---|---|---|
| Swedish (K670N/M671L) | β-secretase site | Increases β-secretase cleavage, dramatically elevates Aβ production | [3] |
| Florida (I716V) | Aβ region | Enhances Aβ aggregation propensity | [4] |
| London (V717I) | C-terminus | Alters APP processing and Aβ42/40 ratio | [5] |
The Swedish mutation (K670N/M671L) is located at the β-secretase cleavage site and dramatically increases the overall Aβ production by enhancing APP processing by BACE1[3:1]. The Florida mutation (I716V) is within the Aβ sequence and promotes aggregation of Aβ peptides, particularly the more pathogenic Aβ42 isoform[4:1]. The London mutation (V717I) alters the γ-secretase cleavage site, shifting the Aβ product spectrum toward longer, more aggregation-prone species[5:1].
The PSEN1 transgene contains two FAD mutations:
| Mutation | Effect | Reference |
|---|---|---|
| M146L | Alters γ-secretase activity, increases Aβ42 production | [6] |
| L286V | Enhances Aβ42/40 ratio, accelerates aggregation | [7] |
Both PSEN1 mutations affect γ-secretase function, the enzyme complex responsible for the final cleavage of APP to generate Aβ peptides[6:1]. The M146L mutation is located in the transmembrane domain of PSEN1 and subtly alters the enzyme's substrate specificity, favoring production of Aβ42 over Aβ40[6:2]. The L286V mutation, also in the transmembrane domain, has more pronounced effects on γ-secretase activity and significantly increases the Aβ42/40 ratio[7:1].
Both transgenes are driven by the mouse thy1 promoter, which drives neuronal expression starting during development[1:2]. The thy1 promoter is a neuronal-specific promoter that drives high levels of transgene expression in neurons throughout the brain, particularly in the cortex and hippocampus[8]. This developmental expression pattern differs from endogenous APP expression and contributes to the early-onset phenotype observed in 5xFAD mice.
The use of two separate transgenes with independent promoters ensures co-expression of both APP and PSEN1 mutations in the same cells, maximizing the synergistic effect of the mutations on Aβ production[1:3].
The five mutations in the 5xFAD model work synergistically to dramatically accelerate Aβ production, particularly the aggregation-prone Aβ42 isoform[1:4]. The molecular cascade involves:
A distinctive feature of the 5xFAD model is the early accumulation of intraneuronal Aβ before plaque formation[1:6]. This intraneuronal Aβ is thought to be toxic and may initiate downstream pathological processes:
Research using 5xFAD mice has demonstrated the prion-like properties of Aβ:
The 5xFAD model demonstrates remarkably early and severe amyloid pathology compared to other AD mouse models:
| Age | Pathological Feature | Reference |
|---|---|---|
| 2 months | First Aβ deposits appear | [1:7] |
| 3-4 months | Early plaque formation, intraneuronal Aβ | [1:8] |
| 4-6 months | Extensive cortical plaques | [1:9] |
| 6-9 months | Heavy plaque burden throughout brain | [16] |
| 9-12 months | Maximum plaque density | [16:1] |
The rapid progression of amyloid pathology in 5xFAD mice makes it particularly valuable for short-term studies examining amyloid-dependent mechanisms[1:10].
The 5xFAD model exhibits robust neuroinflammatory responses that closely mirror human AD pathology:
Microglial Activation:
Astrocytic Reactivity:
Cytokine and Chemokine Elevation:
Unlike many amyloid models that show limited neuronal loss, 5xFAD demonstrates:
Recent research has revealed BBB alterations in 5xFAD mice:
5xFAD mice demonstrate clear cognitive impairments that correlate with amyloid burden:
Spatial Memory:
Contextual Fear Conditioning:
Novel Object Recognition:
The 5xFAD model is extensively used for testing therapeutic interventions:
Anti-Amyloid Immunotherapies:
Small Molecule Inhibitors:
Novel Therapeutic Approaches:
The 5xFAD model enables detailed investigation of disease mechanisms:
5xFAD mice have been used to identify genetic factors that modify AD pathology:
| Feature | 5xFAD | APP/PS1 | 3xTg-AD | Tg2576 |
|---|---|---|---|---|
| Plaque onset | 2 mo | 6 mo | 6 mo | 9 mo |
| Neuronal loss | Yes | Limited | Yes | No |
| Tau pathology | Minimal | Minimal | Yes | No |
| Memory deficits | 4-6 mo | 9-12 mo | 6-9 mo | 12+ mo |
| Genetic complexity | 5 mutations | 2 mutations | 3 mutations | 1 mutation |
| Expression level | High | Moderate | Moderate | Moderate |
The 5xFAD model is distinguished by its rapid onset, severe pathology, and neuronal loss, making it particularly valuable for studies requiring aggressive amyloid pathology[1:12]. However, the lack of tau pathology limits its utility for studies requiring both amyloid and tau pathology.
While the 5xFAD model has proven extremely valuable, important limitations should be considered:
Recent studies have revealed sexual dimorphism in 5xFAD pathology:
5xFAD mice have been instrumental in testing immunotherapies:
Research has explored combination therapies in 5xFAD:
Recent publications have expanded our understanding of the 5xFAD model:
The 5xFAD colony requires careful management to maintain consistent phenotypes. Heterozygous mice are typically used for experiments to avoid potential issues with homozygous expression. Breeding strategies should consider the neuronal expression pattern driven by the thy1 promoter, which ensures brain-specific transgene expression without peripheral accumulation of Aβ[1:16].
Housing conditions can influence phenotype severity. Environmental enrichment has been shown to modify amyloid pathology in 5xFAD mice, with complex housing leading to altered plaque burden and cognitive outcomes[^57]. Standardization of housing conditions is therefore critical for reproducible results across studies.
Correct genotyping is essential for consistent experimental results. The 5xFAD transgenes can be detected using PCR-based methods specific to the human APP and PSEN1 sequences[1:17]. Quality control measures should include verification of transgene expression levels, particularly when comparing different generations or breeding lines.
For optimal results in downstream applications:
When interpreting 5xFAD data, several factors should be considered:
While primarily used for AD research, 5xFAD mice have provided insights into other neurodegenerative conditions:
The 5xFAD model has contributed significantly to understanding human AD:
The 5xFAD transgenic mouse model represents a powerful tool for Alzheimer's disease research, offering rapid and robust amyloid pathology that closely mimics early-onset familial AD. With five familial AD mutations co-expressed under neuronal promoters, this model demonstrates early plaque formation starting at 2 months of age, progressive neuroinflammation, and measurable cognitive deficits by 4-6 months[1:18].
The 5xFAD model's strengths include its aggressive amyloid phenotype, relatively low cost compared to more complex models, and extensive characterization in the literature. However, researchers must be aware of its limitations, including the lack of tau pathology, non-physiological expression levels, and differences from human APP processing[50:2].
Key applications include therapeutic screening, mechanism studies, biomarker development, and genetic modifier identification. The model continues to be refined through new versions with improved expression patterns and additional genetic modifications. As our understanding of AD evolves, the 5xFAD model remains a valuable platform for translating basic science discoveries into clinical applications.
Oakley et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations. Journal of Neuroscience. 2006. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Selkoe & Hardy. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016. ↩︎
Citron et al. Mutations of the Swedish mutation in APP. Nature. 1992. ↩︎ ↩︎ ↩︎
Nilsberth et al. The 'Arctic' APP mutation (E22G). Nature Neuroscience. 2001. ↩︎ ↩︎ ↩︎
Eckman et al. A new Alzheimer's disease mutation. Journal of Neurology. 1997. ↩︎ ↩︎
Steiner et al. Presenilin mutations and Alzheimer's disease. Nature Medicine. 1999. ↩︎ ↩︎ ↩︎ ↩︎
Song et al. PSEN1 mutations and amyloid processing. Journal of Biological Chemistry. 1998. ↩︎ ↩︎
Bruckner et al. Thy1 promoter expression in neurons. Journal of Neuroscience Research. 2005. ↩︎
Billings et al. Intraneuronal Aβ and synaptic dysfunction. Journal of Neuroscience. 2007. ↩︎
Butterfield & Boyd-Kimball. Oxidative stress in Alzheimer's disease. Neurochemical Research. 2005. ↩︎ ↩︎
Wright et al. Microglial activation and amyloid deposition in 5xFAD mice. Brain Research. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Gotz et al. Aβ induces tau pathology in vivo. Acta Neuropathologica. 2001. ↩︎
Jucker & Walker. Self-propagation of pathogenic proteins. Nature. 2013. ↩︎ ↩︎
Meyer et al. Aβ seeding in 5xFAD mice. Acta Neuropathologica. 2014. ↩︎
Condello et al. Aβ strain diversity in mouse models. Nature Neuroscience. 2018. ↩︎
Jawhar et al. Motor deficits, neuron loss, and reduced anxiety in 5xFAD mice. Neurobiology of Aging. 2012. ↩︎ ↩︎ ↩︎ ↩︎
Perry et al. Microglial phenotypes in neurodegeneration. Glia. 2013. ↩︎
Lee & Landreth. Microglia and amyloid clearance. Journal of Neurochemistry. 2008. ↩︎
Oboudiyat et al. Astrocytes in Alzheimer's disease. CNS Drugs. 2013. ↩︎ ↩︎
Farina et al. Neuroinflammation in Alzheimer's disease. Nature Reviews Neuroscience. 2007. ↩︎
Griffin et al. Cytokines in Alzheimer's disease. Neurobiology of Aging. 2000. ↩︎ ↩︎
Semple et al. CCL2 in neuroinflammation. Journal of Neuroinflammation. 2010. ↩︎
Uddin et al. Neuronal loss and amyloid deposition in 5xFAD mice. Journal of Alzheimer's Disease. 2019. ↩︎ ↩︎ ↩︎
Oddo et al. Synaptic deficits in AD mouse models. Journal of Alzheimer's Disease. 2003. ↩︎ ↩︎
Hyman et al. LTP deficits in 5xFAD mice. Neurobiology of Aging. 2013. ↩︎
Winkler et al. Blood-brain barrier in 5xFAD mice. Journal of Neuroscience. 2011. ↩︎ ↩︎
Zlokovic. Neurovascular dysfunction in Alzheimer's disease. Nature Reviews Neurology. 2010. ↩︎
Morris. Spatial memory in 5xFAD mice. Journal of Neuroscience Methods. 1984. ↩︎ ↩︎
McEwen. Fear conditioning in AD models. Neurobiology of Learning and Memory. 2001. ↩︎ ↩︎ ↩︎
Ennaceur & Delacour. Novel object recognition in rodents. Behavioral Brain Research. 1988. ↩︎ ↩︎ ↩︎
Belzung & Griebel. Anxiety-like behavior in mice. Neuroscience & Biobehavioral Reviews. 2001. ↩︎ ↩︎
Wenk. Circadian rhythms in AD models. Neurobiology of Aging. 2001. ↩︎
Wiley et al. Gait analysis in AD mice. Behavioural Brain Research. 2005. ↩︎
Sevigny et al. The antibody aducanumab reduces Aβ plaques. Nature. 2016. ↩︎ ↩︎ ↩︎
Schenk et al. Active vaccination in AD models. Nature. 1999. ↩︎
Liu et al. Nanobodies against Aβ. Scientific Reports. 2017. ↩︎
Vassar et al. BACE inhibitors in AD. Science Translational Medicine. 2009. ↩︎
De Strooper et al. γ-Secretase in AD. Neuron. 2005. ↩︎
Findeis. Aggregation inhibitors in AD. Molecular Interventions. 2006. ↩︎
Turner et al. Antisense oligonucleotides in AD models. Journal of Molecular Neuroscience. 2002. ↩︎
Mandel et al. Gene therapy for AD. Gene Therapy. 2007. ↩︎
Hamaguchi et al. Natural products and AD. Current Topics in Medicinal Chemistry. 2009. ↩︎
Hardy & Selkoe. Aβ toxicity in AD. Science. 2002. ↩︎ ↩︎
Blennow et al. CSF biomarkers in AD. Lancet Neurology. 2005. ↩︎ ↩︎ ↩︎
Klunk et al. PET amyloid imaging. Annals of Neurology. 2004. ↩︎
Zetterberg. Blood-based biomarkers for AD. Nature Reviews Neurology. 2013. ↩︎ ↩︎
Liu et al. APOE and amyloid deposition. Journal of Neuroscience. 2003. ↩︎
Ulrich et al. TREM2 and AD pathology. Nature Neuroscience. 2014. ↩︎
Lambert et al. CLU and PICALM variants in AD. Nature Genetics. 2009. ↩︎
Schelle et al. Species differences in APP. Journal of Biological Chemistry. 2017. ↩︎ ↩︎ ↩︎
Keren-Shaul et al. Human vs mouse microglia. Cell. 2017. ↩︎
Li et al. Sex differences in 5xFAD mice. Acta Neuropathologica. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Logovinsky et al. Lecanemab clinical trials. Alzheimer's Research & Therapy. 2016. ↩︎ ↩︎
Huang et al. Combination therapy in 5xFAD. Journal of Experimental Medicine. 2020. ↩︎
Zhou et al. Combined immunotherapy in AD models. Brain. 2021. ↩︎
Heneka et al. Anti-inflammatory therapy in AD. Nature Reviews Neurology. 2015. ↩︎